FOSFOR-32 RADIONUKLIDI ASOSIDAGI RADIOFARMATSEVTIK DORI VOSITASINING MOLYAR FAOLLIGINI SPEKTROFOTOMETRIK ANIQLASH
##submission.downloads##
Ushbu tadqiqotda tashuvchisiz fosfor-32 (³²P) bilan nishonlangan ortofosfat kislota (H₃[³²P]PO₄) ishlab chiqarish jarayonida
preparatning molyar faolligini (Ci/mmol) tezkor baholash uchun vanadiy–molibden reaktivi asosidagi sezgir spektrofotometrik
usul ishlab chiqildi. Fosfat ionining vanadat va molibdat ionlari bilan nitrat kislota muhitida hosil qiladigan sariq fosfor– vanadiy–
molibden (P–V–Mo) kompleksi 410 nm to‘lqin uzunligida maksimal yutilish beradi. Kalibrovka tenglamasi d = 0,07812·n +
0,00783 (n×10 ⁸ mol), R² = 0,9993 bo‘lib, usulning⁻ chiziqliligini tasdiqlaydi. Aniqlash chegarasi (LOD) 0,17 mkg, miqdoriy
aniqlash chegarasi (LOQ) 0,56 mkg, ishchi (chiziqli) diapazon 0,31–4,96 mkg fosforni tashkil etdi. Amaliy namuna uchun molyar
faollik 8410 Ci/mmol bo‘lib, nazariy qiymatdan chetlanish 1,06% ekanligi aniqlandi.
1. Tennvall J, Brans B. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. Eur J Nucl Med
Mol Imaging. 2007; 34: 1324.
2. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269.
3. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background.
Semin Nucl Med 1992;22:11.
4. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46:38S.
5. Das T, Pillai MRA. Options to meet the future global demand of radioisotopes for radionucldie therapy. Nucl Med Biol
2013;40:23.
6. Banerjee S, Das T, Chakraborty S, Venkatesh M. Emergence and present status of Lu-177 in targeted radiotherapy: The
Indian scenario. Radiochim Acta 2012;100:115.
7. Cheng Y., Kiess A.P., Herman J.M., Pomper M.G., Meltzer S.J., Abraham J.M. Phosphorus-32,a Clinically Available Drug,
Inhibits Cancer Growth by Inducing DNA Double-Strand Breakage. PLOS ONE // 2015; 1-11.
8. G.V.S. Ashok Kumar, J. Vithya, R. Kumar, C. R. Venkata Subramani. Development of a flowsheet for the radiochemical
processing of irradiated sulphate targets for the production of carrier-free 32P. Journal of Radioanalytical and Nuclear
Chemistry. 2014; 302:939-945.
9. Silva M, Luck JV, Siegel ME (2001) 32P chromic phosphate radiosynovectomy for chronic haemophilic synovitis.
Haemophilia 7(2):40–49
10. Prabhakar G, Sachdev SS, Umamaheswari S, Sivaprasad N, Bhatia MH, Chaudhari PR, Solav SV (2007) Development of
samarium [32P] phosphate colloid for radiosynoviorthesis applications: preparation, biological and preliminary clinical
studies experience. Appl Radiat Isot 65(12):1309– 1313
11. Pandey U, Saxena SK, Sarma HD, Tandon P, Ram R, Samuel G, Dash A, Venkatesh M (2008) Bioevaluation studies of 32P
incorporated mould brachytherapy sources for potential application in treatment of superficial tumors. Nucl Med Commun
29:717–723
12. Vivante H, Salgueiro M.J, Ughetti R, Nicolini J, Zubillaga M (2007) 32P-patch contact brachyradiotherapy in the
management of recalcitrant keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol 73:336–339
Mulkiiyat (c) 2026 «O‘zMU XABARLARI»
Ushbu ish quyidagi litsenziya asosida ruxsatlangan Kreativ Commons Attribution-NonCommercial-ShareAlike 4.0 International litsenziyasi asosida bu ish ruxsatlangan..
.jpg)
.png)
